Explore 3 Stock Ideas & Industry Insights Download Free Report

800-234-336
Shopping Cart 0
countryflagNZ
Login

Avita Medical Inc

Healthcare AU AVH

1.11AUD
0.00(0%)

Last update at 2026-06-26T04:54:00Z

Day Range

1.081.12
LowHigh

52 Week Range

1.001.98
LowHigh

Fundamentals

  • Previous Close 1.11
  • Market Cap173.12M
  • Volume194951
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-37.11000M
  • Revenue TTM72.35M
  • Revenue Per Share TTM2.50
  • Gross Profit TTM 58.86M
  • Diluted EPS TTM-0.44

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2025-06-30 2024-12-31 2024-06-30 2023-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2025-06-30 2024-12-31 2024-06-30 2023-12-31
Income before tax -50.26998M -61.79100M -61.79100M -35.31500M -35.31500M
Minority interest - - - - -
Net income -50.28137M -61.84500M -61.84500M -35.38100M -35.38100M
Selling general administrative 80.51M 33.20M 33.20M 65.54M 65.54M
Selling and marketing expenses - 58.20M 58.20M - -
Gross profit 60.87M 55.16M 55.16M 42.58M 42.58M
Reconciled depreciation 2.35M 1.13M 1.13M 0.63M 0.63M
Ebit -43.39636M -56.43000M -56.43000M - -
Ebitda -40.96751M -55.30400M -55.30400M - -
Depreciation and amortization 2.43M 1.13M 1.13M - -
Non operating income net other - - - - -
Operating income -43.39636M -56.59300M -56.59300M -42.65500M -42.65500M
Other operating expenses 117.50M 120.84M 120.84M - -
Interest expense 5.18M 8.13M 8.13M 1.14M 1.14M
Tax provision 0.01M 0.05M 0.05M 0.07M 0.07M
Interest income - 5.36M 5.36M -1.14300M 1.14M
Net interest income -5.00400M -5.36100M -5.36100M -1.14300M -1.14300M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense 0.01M 0.05M 0.05M - -
Total revenue 74.11M 64.25M 64.25M 50.14M 50.14M
Total operating expenses 104.26M 111.75M 111.75M 92.80M 92.80M
Cost of revenue 13.24M 9.09M 9.09M 7.56M 7.56M
Total other income expense net -6.87362M -5.19800M -5.19800M 8.48M 8.48M
Discontinued operations - - - - -
Net income from continuing ops -48.58700M -61.84500M -61.84500M -35.38100M -35.38100M
Net income applicable to common shares - -61.84500M -61.84500M -35.38100M -35.38100M
Preferred stock and other adjustments - - - - -
Breakdown 2025-12-31 2025-06-30 2024-12-31 2024-06-30 2023-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2025-06-30 2024-12-31 2024-06-30 2023-12-31
Total assets 56.43M 79.71M 79.71M 111.64M 111.64M
Intangible assets 5.65M 5.57M 5.57M 0.49M 0.49M
Earning assets - - - - -
Other current assets 1.27M 1.88M 1.88M - 0.04M
Total liab 69.39M 75.21M 75.21M 62.58M 62.58M
Total stockholder equity -16.66124M 4.50M 4.50M 49.06M 49.06M
Deferred long term liab - - - - -
Other current liab 9.78M 0.42M 11.51M 0.34M 0.37M
Common stock 0.00300M - 0.00300M - 0.00300M
Capital stock 0.00300M 0.00300M 0.00300M 0.00300M 0.00300M
Retained earnings -408.67659M -359.81400M -359.81400M -297.96900M -297.96900M
Other liab - - - - -
Good will - - - - -
Other assets - - 3.55M - 2.83M
Cash 10.25M 14.05M 14.05M 22.12M 22.12M
Cash and equivalents - - 14.05M - 22.12M
Total current liabilities 62.72M 20.16M 20.16M 13.20M 13.20M
Current deferred revenue 0.03M - - - -
Net debt 37.97M 28.20M 31.93M 17.69M 17.69M
Short term debt 43.94M - 2.35M - 0.00000M
Short long term debt 42.98M - - - -
Short long term debt total 48.22M - 45.98M - -
Other stockholder equity 394.67M - 367.57M - -3.01700M
Property plant equipment - - 13.59M - 4.32M
Total current assets 35.51M 57.00M 57.00M 104.01M 104.01M
Long term investments - - - 0.00000M 0.00000M
Net tangible assets - - - - -
Short term investments 7.95M 21.84M 21.84M 66.94M 66.94M
Net receivables 9.11M 11.79M 11.96M 7.66M 7.66M
Long term debt - 42.24M 42.24M 39.81M 39.81M
Inventory 6.93M 7.27M 7.27M 5.60M 5.60M
Accounts payable 8.97M 6.29M 6.29M 3.79M 3.79M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income -2.66179M - -3.25800M - -
Additional paid in capital - - - - -
Common stock total equity - - - - -
Preferred stock total equity - - - - -
Retained earnings total equity - - - - -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 3.73M 3.55M 3.55M 2.53M 2.83M
Deferred long term asset charges - - - - -
Non current assets total 20.92M 22.71M 22.71M 7.63M 7.63M
Capital lease obligations 3.06M 3.74M 3.74M 2.60M 2.60M
Long term debt total - - 42.24M - 39.81M
Breakdown 2025-12-31 2025-06-30 2024-12-31 2024-06-30 2023-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2025-06-30 2024-12-31 2024-06-30 2023-12-31
Investments 14.19M 37.36M 37.36M 1.61M 1.61M
Change to liabilities - - - - -
Total cashflows from investing activities 12.89M 37.36M 37.36M 1.61M 1.61M
Net borrowings - 0.00000M 0.00000M 38.76M 38.76M
Total cash from financing activities 15.46M 3.51M 3.51M 40.37M 40.37M
Change to operating activities - - - - -
Net income -50.28137M -61.84500M -61.84500M -54.08340M -54.08340M
Change in cash -4.89273M -8.06800M -8.06800M 3.95M 3.95M
Begin period cash flow 15.14M 22.12M 22.12M 18.16M 18.16M
End period cash flow 10.25M 14.05M 14.05M 22.12M 22.12M
Total cash from operating activities -32.28286M -48.93900M -48.93900M -38.01100M -38.01100M
Issuance of capital stock 14.79M - 0.00000M - -
Depreciation 2.43M 1.13M 1.13M 0.63M 0.63M
Other cashflows from investing activities -0.65714M -0.16200M -0.16200M 2.99M 2.99M
Dividends paid - - - - -
Change to inventory -0.48432M -2.16000M -2.16000M -3.69300M -3.69300M
Change to account receivables 3.76M -4.14500M -4.14500M -4.17200M -4.17200M
Sale purchase of stock - 3.51M 3.51M 1.61M 1.61M
Other cashflows from financing activities 0.82M 0.27M 0.27M - -
Change to netincome - - - - -
Capital expenditures 1.04M 9.33M 9.33M 1.45M 1.45M
Change receivables - - - - -
Cash flows other operating - - - - -
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - - -
Change in working capital 3.56M -4.98500M -4.98500M -6.57400M -6.57400M
Stock based compensation 9.52M 13.50M 13.50M 8.38M 8.38M
Other non cash items 12.01M 3.27M 3.27M 4.61M 4.61M
Free cash flow -33.32291M -58.27200M -58.27200M -39.45800M -39.45800M

Peer Comparison

Sector: Healthcare Industry: Medical Devices

Company Change (AUD) Price (AUD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
AVH
Avita Medical Inc		 - -% 1.11 - 9.97 2.39 7.17 2.14 15.37
COH
Cochlear Ltd		 1.17 1.00% 117.72 21.65 21.14 3.20 3.76 3.14 12.98
4DX
4DMEDICAL Ltd		 -0.44 9.63% 4.13 - - 395.52 37.59 380.32 -7.2899
AVR
Anteris Technologies Global Corp		 -0.57 3.86% 14.20 - - 715.21 3.10 336.79 -5.1986
PNV
Polynovo Ltd		 -0.033 3.49% 0.91 102.00 33.56 5.05 8.48 5.03 101.00

Reports Covered

Stock Research & News

View All

Profile

AVITA Medical, Inc., together with its subsidiaries, operates as a therapeutic acute wound care company in the United States, Japan, the European Union, Australia, and the United Kingdom. The company's lead product is the RECELL System, a cell harvesting device used for the treatment of thermal burn wounds and full-thickness skin defects, as well as for repigmentation of stable depigmented vitiligo lesions. It also provides RECALL autologous cell harvesting device, which can treat areas of up to 1,920 cm2; RECELL autologous cell harvesting device with ease-of-use, an enhanced ease-of-use device that can treat areas of up to 1,920 cm²; and RECELL GO mini autologous cell harvesting device, a line extension of the RECELL GO system to treat smaller wounds up to 480 cm2, as well as RECELL GO autologous cell harvesting device consisting of RECELL GO processing device, which controls and manages the pressure applied to disaggregate the donor skin cells and controls the incubation time of the RECELL Enzyme to optimize cell yield and promote cell viability; and RECELL GO preparation kit, which can treat areas up to 1,920 cm2. In addition, the company sells and distributes PermeaDerm, a biosynthetic wound matrix and Cohealyx, a collagen-based dermal matrix. It serves hospitals, treatment centers, and distributors. The company was formerly known as AVITA Therapeutics, Inc. and changed its name to AVITA Medical, Inc. in December 2020. AVITA Medical, Inc. is headquartered in Valencia, California.

Avita Medical Inc

28159 Avenue Stanford, Valencia, CA, United States, 91355

Key Executives

Name Title Year Born
Mr. James M. Corbett CEO, Pres & Exec. Director 1958
Mr. Michael Bria Holder MBA Chief Financial Officer 1963
Ms. Kathy M. McGee Chief Operating Officer 1966
Mr. Andrew Quick Chief Technology Officer 1971
Ms. Donna Shiroma Gen. Counsel & Sec. 1962
Ms. Erin Liberto Chief Commercial Officer 1975
Mr. David Fencil VP of Global Operations NA
Ms. Debbie Garner VP of Global Marketing NA
Mr. James M. Corbett CEO, President & Executive Director 1958
Ms. Donna Shiroma General Counsel & Secretary 1962

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.